Hormonal decline is one of the most noticeable dimensions of aging. Testosterone, growth hormone, thyroid hormones, and DHEA all decrease with age — and the question of whether to replace, optimize, or accept these declines is one of the most actively debated topics in longevity medicine. GLP-1 receptor agonists like semaglutide and tirzepatide have introduced an entirely new pharmacological dimension to metabolic health optimization.
This category covers the hormonal landscape of aging with the nuance it demands. We examine the evidence for and against testosterone replacement, growth hormone secretagogues, thyroid optimization, and peptide therapies — separating the interventions with strong clinical evidence from those with more hype than data. Each article covers mechanism of action, clinical trial data, dosing protocols used in research, side effect profiles, and the practical question of whether the intervention is worth considering at your specific age and health status.